US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.39 against a street estimate of 0.30 — a beat of 30.0%.
Analysts rate Supernus Pharmaceuticals Inc a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $61.75.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.12% |
| Millennium Management LLC | 6.62% |
| Vanguard Portfolio Management, LLC | 5.57% |
| Vanguard Capital Management, LLC | 4.24% |
| State Street Corp | 3.93% |
| Dimensional Fund Advisors, Inc. | 3.57% |
| Delaware Management Holdings Inc | 3.50% |
| Armistice Capital, LLC | 3.26% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SUPERNUS PHARMACEUTICALS, INC. - FORM 10-Q SUMMARY Six Months Ended June 30, 2026 --- HEADLINE NUMBERS • Net product sales: $316.5 million (six mon | 2026-08-03 |
| Company announcement · Q3 2026 SUPERNUS PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Filing Date: August 3, 2026 • Company: Supernus Pharmaceuticals, Inc. (Ticker: | 2026-08-03 |
| Company announcement · Q3 2026 SUPERNUS PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Merger announcement date: August 3, 2026 • Companies involved: Supernus Pharmac | 2026-08-03 |
| Results announced · Q3 2026 SUPERNUS PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues: $219.1 million in Q2 2026, up 32% year-over-year ($165.5 millio | 2026-08-03 |
| Material agreement · Q3 2026 SUPERNUS PHARMACEUTICALS MERGER SUMMARY HEADLINE NUMBERS • Exchange Ratio: Each Supernus share converts to 1.5401 Indivior shares (fixed, non-adjust | 2026-08-03 |
| Quarterly report · Q1 2026 SUPERNUS PHARMACEUTICALS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net product sales: $150.8 million (Q1 2026) vs $142.0 million (Q1 2025), up | 2026-05-05 |
| Proxy statement · Q2 2026 SUPERNUS PHARMACEUTICALS, INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two (2) directors for three-year t | 2026-04-30 |
| Annual report FY2025 SUPERNUS PHARMACEUTICALS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Biopharmaceutical firm focused on central nervous sys | 2026-03-02 |
Readable in the app.
| Announcement | Date |
|---|---|
| Merger agreement entered into with Indivior Pharmaceuticals Inc. Supernus Pharmaceuticals agreed to merge with Indivior Pharmaceuticals in an all-stock deal announced August 1, 2026. Supernus shareholders will receive 1.5401 Indivior shares for each Super | 2026-08-03 |
| Proposed merger with Indivior Pharmaceuticals announced; conference call scheduled Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they are hosting a conference call on August 3, 2026 at 8:30 a.m. ET to discuss their proposed merger. This is a procedural an | 2026-08-03 |
| Proposed merger of equals with Indivior Pharmaceuticals announced Supernus Pharmaceuticals announced a proposed 'merger of equals' with Indivior Pharmaceuticals on August 3, 2026. The company informed employees and the public through LinkedIn and internal | 2026-08-03 |
| Definitive agreement to combine with Indivior in all-stock merger Supernus Pharmaceuticals announced Q2 2026 financial results on August 3, 2026, and revealed it has agreed to merge with Indivior Pharmaceuticals in an all-stock deal structured as a 'merger | 2026-08-03 |
| Acquired assets and intellectual property rights for NV-5138 compound from Navitor Supernus Pharmaceuticals acquired all rights to NV-5138 (also called SPN-820), a pharmaceutical compound, from Navitor Pharmaceuticals on April 1, 2026. This deal was contemplated under agre | 2026-04-07 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Supernus Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.